AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

AbbVie Announces Supplemental New Drug Application

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL) – If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the

AbbVie Announces Supplemental New Drug Application

Oct 17, 2018 · AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic

AbbVie Announces Supplemental New Drug Application

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated

AbbVie : Announces Supplemental New Drug Application

AbbVie : Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

AbbVie Announces Supplemental New Drug Application

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Details Category: Small Molecules Published on Friday, 19 October 2018 12:13 Hits: 416

AbbVie : Announces Supplemental New Drug Application

NORTH CHICAGO, Ill. – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for IMBRUVICA (ibrutinib) in combination with obinutuzumab (GAZYVA) in previously untreated adult patients with chronic lymphocytic leukemia or small lymphocytic

AbbVie Announces Supplemental New Drug Application

All Rights Reserved. For more information on this site, please read our Privacy Policy, Terms of Service, and Ad Choices. Privacy Policy, Terms of Service, and Ad

AbbVie (ABBV) Announces sNDA Accepted for Priority Review

AbbVie (ABBV) Announces sNDA Accepted for Priority Review by FDA for IMBRUVICA in Combination with Obinutuzumab for Previously Untreated CLL

AbbVie Announces Ibrutinib (IMBRUVICA®) Supplemental New

AbbVie Announces Ibrutinib (IMBRUVICA®) Supplemental New Drug Application for Previously Treated Chronic Graft-Versus-Host-Disease (cGVHD) Accepted for Review by U.S. FDA – If approved, ibrutinib will be the first therapy specifically approved for patients with cGVHD after failure of one or more lines of systemic therapy